Immunoglobulin A Nephropathy as the First Clinical Presentation of Wilson Disease: A Case Report and Literature Review

Yong-Zhe Zhang  
China Medical University

Geng Jian  
Southern Medical University

Ping He  
China Medical University

Rui Yu  
China Medical University

Mi Tian  
China Medical University

Yan Wu  
China Medical University

Bei-Ru Zhang  
xiaopei19730704@163.com  
China Medical University

Case Report

Keywords: proteinuria, IgA nephropathy, wilson disease

Posted Date: June 11th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-606943/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

**Background:** Wilson disease (WD) is a rare genetic disorder of copper metabolism. The difference in copper tissue accumulation lead to various clinical manifestations, including some atypical presentations. The complex clinical picture makes it easy to miss and misdiagnose, even delay the best chance for treatment.

**Case presentation:** A 26-year-old male patient who had nephritis-range proteinuria and elevated serum creatinine. The renal pathology indicated Immunoglobulin A (IgA) nephropathy and tubular injury which was inconsistent with glomerular lesions. Cirrhosis was also detected by imaging examination. Considering both kidney injury and liver damage, WD was suspected. According to further detected results of abnormal copper metabolism, corneal Kayser-Fleischer rings (K-F rings), and genetic disorder of ATP7B gene, he was finally diagnosed as a case of WD. The patient was given oral penicillamine and zinc sulfate daily and he was also prescribed losartan to control proteinuria on the premise of monitoring renal function and blood pressure. During the 2 years follow-up, the patient's 24h uric cooper dropped to normal. The sign of tremor hands disappeared. The Urine protein and renal function keep stable. The patient had normal liver function and maintained good quality of daily life.

**Conclusions:** In some cases, IgA nephropathy patients with suspicious and unexplained neurological and liver symptoms cannot be ignored. They may eventually be diagnosed with WD.

1. Introduction

WD, also known as hepatolenticular degeneration, is an autosomal recessive hereditary copper metabolic disorder disease. The widely cited prevalence of WD is 1 in 30,000, and its onset age is mostly between 5 and 35[1]. The pathogenic gene of WD is localized to ATP7B on chromosome 13q14.3, which causes a weakened or loss of P-type copper transport ATPase function, resulting in decreased serum ceruloplasmin synthesis and gallbladder copper-discharging dysfunction. The most common clinical manifestations of WD include liver disease and cirrhosis, neurological disorder, and K-F rings at the corneal limbus. Its diagnosis is usually established by typical clinical symptoms, signs and examinations, especially serum ceruloplasmin and uric copper level, and also by the mutation analysis in the ATP7B gene. Some patients may have a positive family history. As one of the few treatable genetic diseases, if patients of WD can be timely and accurately diagnosed and treated in the early stage of disease, most of them can achieve a life quality and life expectancy similar to normal people. However, if the patient starts treatment in the late stage of disease, the treatment is basically invalid, and its lethality and disability rate are relatively high. Therefore, the identification of this disease correctly and timely is extremely critical. What bothers the doctors is that the face of WD is sometimes hidden behind some atypical symptoms, which may be manifested in different tissues, organs or systems. These patients with complex and varied clinical manifestations of WD are easily misdiagnosed or neglected, leading to poor prognosis. As a less common initial presentation of WD, renal injury has been described in some case series with small
samples [2]. This article reports a case of foam urine as the only clinical symptom and finally diagnosed as WD.

2. Case Presentation

A 26-year-old male patient complained that he had foam urine for three years, but the reason why patients are admitted to the clinic was that proteinuria was found in his routine physical examination one month ago. Laboratory data was as follows: urine analysis showed proteinuria (dipstick 2+) and hematuria (3+), 24h uric protein quantification was 0.75g/d (normal range, 0-0.15 g/d), serum creatinine (Scr) was 151umol/L (normal range, 88–104 umol/L). In view of the abnormalities in examination indicators, the patient was admitted to the nephrology with the initial diagnosis of glomerulonephritis and renal insufficiency.

Further detailed consultation and examination were carried out. The patient felt no other discomfort. His routine physical examinations showed no obvious abnormalities. He had no edema, no hypertension and his urine output was normal. During neurological examination, the patient was found to have imperceptible tremor hands. As to the past history, the patient had allergic purpura 22 years ago and pneumothorax 7 years ago. He denied alcohol consumption and history of any drug abuse. He also denied the history of hepatitis and family history of chronic diseases and genetic disease. His parents were not consanguineous marriage. Laboratory examinations indicated normal white blood cell and hemoglobin level. Urinalysis showed 2+ proteinuria with microhematuria (about 100 erythrocytes per high-power field). His 24h uric protein quantitative fluctuated in 0.75-1.1g / d. Abnormal renal function with Scr of 150-170umol/L was founded. While the liver function was normal, and others such as serum electrolytes, thyroid function, C-reactive protein, ASO, serum complement (C3 and C4) were also within the normal range. The immunoglobulin levels were normal of IgG and IgM, except for mild elevation of IgA (3.73g/L, normal range 0.97-3.2g/L). Serologic tests were negative for antinuclear antibody, antineutrophil cytoplasmic antibody, anti-GBM antibody, anti-hepatitis B virus, and anti-hepatitis C virus antibodies.

We performed a renal biopsy to identify kidney disease. Renal biopsy through light microscope showed mesangial cells and matrix proliferation with glomeruli focal segmental hyperplasia and sclerosis (1/10 glomerulus) (Fig. 1A). The epithelial cells were vacuolated and granular degeneration, and brushing margins disappeared, lumen dilated, focal atrophy (atrophy area was about 15%) in part renal tubule. Interstitial focal inflammatory cells infiltrated accompanied by fibrosis, and the walls of arterioles had no obvious pathological changes (Fig. 1B). Immunofluorescence staining shows granular depositon of IgA+++ in mesangium (Fig. 1C). No glomeruli was found by electron microscopy. Silver staining showed tubule bristles shed and interstitial edema (Fig. 1D). The pathologic diagnosis was focal hyperplastic IgA nephropathy accompanied with acute tubular interstitial injury (Lee grade III, Oxford grade M1E0S0T1).

According to the hematuria, proteinuria and renal biopsy, it is easy to diagnose the patients as IgA nephropathy. But there are some doubts about renal pathological. Firstly, the pathological changes of IgA
nephropathy could not explain renal dysfunction. Secondly, the degree of tubular injury was not consistent with glomerular lesions. It was valid to consider that other reason, but not IgA nephropathy might attribute to tubular injury. More important, the young patient presented with liver atrophy and splenomegaly identified by liver MRI without a clear etioloty. And combine that with the non-specific neurological abnormality of his tremor hands, WD was considered a possible diagnosis.

Renal biopsy was reexamined and found some neglected subtle changes. There seemed to be granular deposition in the cytoplasm of renal tubules epithelial cells by light microscope (Fig. 2A). While under electron microscopy, some renal tubular epithelial cells showed degeneration of mitochondria in the cytoplasm. The size of mitochondria varied, the inner and outer membranes were separated, and the cristae became shorter and disappeared (Fig. 2B). The lysosomes increased, and some round granules were deposited in the lysosome (Fig. 2C). Special copper staining, TIMM’S copper staining, suggested brown to black deposits in some renal tubular epithelial cells (Fig. 2D). Measurements of copper metabolism further confirmed the diagnosis of WD: lower levels of serum ceruloplasmin (0.02g/L, normal range 0.27–0.47g/L), and increased urinary excretion of copper (260.4µg/d, normal range 10–60g/d) although accompanied by normal copper serum levels (12.52 µmol/L, normal range 7.12–21.29 µmol/L). The existence of K-F rings in the patient’s eyes by slit lamp examination also supported WD. To confirm the diagnosis of WD, we performed DNA sequence analysis and identified two mutations on the ATP7B gene, which one was known pathogenic mutations, the other was suspicious pathogenic mutations (Table.1). Finally, the patients was diagnosed as WD. The kidney damage was identified as WD associated renal injury, including renal tubulointerstitial injury and focal proliferative IgA nephropathy.

The patient then accepted targeted treatment, including penicillamine 250mg twice daily and oral zinc sulfate. Meanwhile, he was prescribed with losartan to control proteinuria on the premise of monitoring renal function and blood pressure. During the 2 years follow-up, the sign of tremor hands disappears. His 24h uric protein quantification fluctuated in 0.3-0.5g/d. Renal function was reversed and Scr was maintained about 110-130umol/L. 24h uric cooper dropped from 260.4 ug to 69 ug. The patient still had normal liver function and maintained good quality of daily life.

3. Discussion

It is widely accepted that WD is not as rare as once believed, especially after the identification of ATP7B[3]. Since abnormal biliary excretion of copper due to ATP7B gene mutation is the etiology, liver abnormalities are the most common initial manifestation and 40–70% patients diagnosed as WD are on the basis of the presence of liver lesions[4]. In this case, coexistence of asymptomatic and unexplained cirrhosis become the key of diagnosis of this patients. Neuropsychiatric symptoms are another common findings which are at a rate of 50%[5],and the tremor hands is another clue in our case. Till to now, many atypical organs with copper deposition are reported and this leads to different and complex corresponding clinical symptoms and also leads to difficulty of diagnosis (Table.2). Given the difficulties of diagnosing WD, a weighted diagnostic scoring system, also known as Leipzig criteria, are established to help clinicians to evaluate patients for WD better. The system encompasses many key investigations
involving clinical, biochemical, and even molecular genetic testing for making the diagnosis[6]. Although WD can be diagnosed with increased accuracy given better understanding of the disorder and also the addition of molecular diagnostic testing, one thing has not changed with time that WD is still a disease which can be delayed or missed the diagnosis easily. Therefore, the report of special cases will make clinicians better aware of the disease.

In this case, the patient’s earliest symptoms appeared in adulthood and kidney abnormalities including hematuria, proteinuria and renal dysfunction are his initially manifested. Renal involvement is a relatively rare manifestation, especially as initial presentation of WD. Some case reports have demonstrated that renal involvement has different manifestation, such as glomerulonephritis, nephrotic syndrome, IgA nephropathy, IgM nephropathy, even renal function impairment. However, renal tubular function disorder, which can manifest renal tubular acidosis, aminoaciduria, and Fanconi syndrome, is relatively common compare to glomerular injury. A retrospective study analyzed 25 children with WD involving with renal injury and proved that renal tubular injury is relatively common injury. This is mainly attributed to the more deposition of copper in the epithelium of proximal and distal convoluted tubules, which cause basement membrane thicken and further interfere with the reabsorption function of renal tubules. In our case, a relatively serious tubular injury inconsistent with glomerular lesions was found. It further proved the deposition of copper in tubular epithelial cells. IgA nephropathy is another pathologic change in the case. At present, the precise pathogenesis of IgA nephropathy associated with WD remains uncertain. While IgA nephropathy is more likely to be associated with WD-induced liver damage than with the direct copper deposition, since no copper depositons were found in glomeruli, such as in our case or another cases[7]. But different from our case, in that case, the kidney showed only IgA nephropathy without tubular damage, and no copper deposition in tubular epithelial cells. In some studies, it had been mentioned that the decreased ability of the liver to clear immunoglobulin and immune complexes may lead to their increase in serum and deposition in the glomerulus, thereby causing nephropathy and membranoproliferative glomerulonephritis (MPGN). Gunduz reported a case of a boy diagnosed with WD, whose liver injury had manifested as cirrhosis, the renal biopsy histopathology showed MPGN with deposition of IgA[8]. Similarly, a report described a case in Pakistan of WD complicated with IgM nephropathy[9].

Although the clinical manifestations, kidney pathology and abnormal copper metabolism of this patient nearly confirm the diagnosis of WD, investigation of gene mutation is necessary. There are several disorders appear to qualify as mimics of WD, also known as disease-mimic of WD[10]. For example MEDNIK syndrome with mutations in AP1S1 have manifestations including liver damage consistent with WD, neurological involvement, even with low serum ceruloplasmin, elevated basal 24h urinary copper excretion and some degree of hepatocellular copper overload[11]. In this case, there are two mutations in ATP7B identified to support the diagnosis. Till to now, there are more than 500 known disease-associated mutations, but no single mutation is regarded as dominant mutation. Most patients are compound heterozygotes with a different mutation on each allele of the gene[12]. May be the different mutation in one patient contribute to the individually manifestation.
Once a diagnosis of WD is established, treatment must be initiated. D-penicillamine and zinc salts are still standard first-line treatment. After treatment, symptoms of the patient are relieved. In recent years, efforts have been made to find new drugs to treat WD, including oral medicines (such as trientine) that increase life-long adherence [13], and methanobactins, a new drug that promotes copper excretion[14]. New therapeutic strategies are still in need [15, 16].

In conclusion, our case is a rare case of WD with kidney disease as the first symptom. We reported the first case that IgA nephropathy and renal tubular injury caused by copper deposition coexist in WD patients, which is also a very important clue for us to analyze the condition and ultimately diagnose WD. From the case, we should know the possibility of WD in patients of renal disease, especially with suspicious neurological or hepatic abnormalities. Although with the improvement of copper metabolism monitoring methods and the popularization of gene monitoring, the diagnosis of WD has become more and more convenient and accurate, the disease is still an easily missed and misdiagnosed disease, so case report is helpful for clinicians to know more about special WD disease and improve the diagnostic rate.

**Abbreviations**

WD: Wilson disease; IgA: Immunoglobulin A; K-F rings: Kayser-Fleischer rings; Scr: serum creatinine; MPGN: membranoproliferative glomerulonephritis;

**Declarations**

**Consent to participate:**

Informed consent was obtained from the patient.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The relevant data and materials pertaining to this study are available upon request.

**Competing interests**

The authors declare that no conflict of interests exists.

**Funding**
Authors’ contributions

Research idea and study design: BZ; data acquisition: YZ and JG; data analysis/interpretation: YZ, PH, RY, MT, and YW; statistical analysis: YZ; supervision or mentorship: JG.

Acknowledgment

Patient has provided informed consent for publication of the case.

Author details

1 Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

2 Department of Pathology, Southern Medical University

References

1. Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol. 2015;14(1):103–13.
2. Pfister ED. [Wilson's disease: What has been confirmed in diagnostic and therapy?]. Der Internist. 2017;58(12):1233–41.
3. Coffey AJ, Durkie M, Hague S, McClay K, Emmerson J, Lo C, Klaffke S, Joyce CJ, Dhawan A, Hadzic N, et al. A genetic study of Wilson's disease in the United Kingdom. Brain. 2013;136(Pt 5):1476–87.
4. Biswas S, Paul N, Das SK. Nonmotor Manifestations of Wilson's Disease. International review of neurobiology. 2017;134:1443–59.
5. Ranucci G, Socha P, Iorio R. Wilson disease: what is still unclear in pediatric patients? Clinics research in hepatology gastroenterology. 2014;38(3):268–72.
6. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, Schilsky M, Cox D, Berr F. Diagnosis and phenotypic classification of Wilson disease. Liver international: official journal of the International Association for the Study of the Liver. 2003;23(3):139–42.
7. Shimamura Y, Maeda T, Gocho Y, Ogawa Y, Tsuji K, Takizawa H. Immunoglobulin A nephropathy secondary to Wilson's disease: a case report and literature review. CEN case reports. 2019;8(1):61–6.
8. Gunduz Z, Dusunsel R, Anarat A. Wilson cirrhosis associated with membranoproliferative glomerulonephritis. Nephron. 1996;74(2):497–8.
9. Ul Abideen Z, Sajjad Z, Haroon Khan A, Mamoon N, Bilal M, Mujtaba Quadri KH. Immunoglobulin M Nephropathy in a Patient with Wilson's Disease. Cureus. 2016;8(12):e929.
10. Roberts EA. Update on the Diagnosis and Management of Wilson Disease. Curr Gastroenterol Rep. 2018;20(12):56.

11. Martinelli D, Travaglini L, Drouin CA, Ceballos-Picot I, Rizza T, Bertini E, Carrozzo R, Petrini S, de Lonlay P, El Hachem M, et al. MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. Brain. 2013;136(Pt 3):872–81.

12. Schilsky ML. Wilson Disease: Diagnosis, Treatment, and Follow-up. Clinics in liver disease. 2017;21(4):755–67.

13. Ala A, Aliu E, Schilsky ML. Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease. Digestive diseases sciences. 2015;60(5):1433–9.

14. DiSpirito AA, Semrau JD, Murrell JC, Gallagher WH, Dennison C, Vuilleumier S. Methanobactin and the Link between Copper and Bacterial Methane Oxidation. Microbiology molecular biology reviews: MMBR. 2016;80(2):387–409.

15. Murillo O, Luqui DM, Gazquez C, Martinez-Espartosa D, Navarro-Blasco I, Monreal JL, Guembe L, Moreno-Cermeno A, Corrales FJ, Prieto J, et al. Long-term metabolic correction of Wilson's disease in a murine model by gene therapy. Journal of hepatology. 2016;64(2):419–26.

16. Moreno D, Murillo O, Gazquez C, Hernandez-Alcocoba R, Uerlings R, Gonzalez-Aseguinolaza G, Weiskirchen R. Visualization of the therapeutic efficacy of a gene correction approach in Wilson's disease by laser-ablation inductively coupled mass spectrometry. Journal of hepatology. 2018;68(5):1088–90.

17. Lorincz MT. Neurologic Wilson's disease. Ann N Y Acad Sci. 2010;1184:173–87.

18. Langwinska-Wosko E, Litwin T, Dziezyc K, Czlonkowska A. The sunflower cataract in Wilson's disease: pathognomonic sign or rare finding? Acta Neurol Belgica. 2016;116(3):325–8.

19. El Raziky MS, Ali A, El Shahawy A, Hamdy MM: Acute hemolytic anemia as an initial presentation of Wilson disease in children. Journal of pediatric hematology/oncology 2014, 36(3):173–178.

20. Kapoor N, Cherian KE, Sajith KG, Thomas M, Eapen CE, Thomas N, Paul TV: Renal Tubular Function, Bone Health and Body Composition in Wilson's Disease: A Cross-Sectional Study from India. Calcified tissue international 2019.

21. Tsuchiya M, Takaki R, Kobayashi F, Nagasaka T, Shindo K, Takiyama Y. Multiple pseudofractures due to Fanconi's syndrome associated with Wilson's disease. Rinsho shinkeigaku = Clinical neurology. 2017;57(9):527–30.

22. Azizi E, Eshel G, Aladjem M. Hypercalciuria and nephrolithiasis as a presenting sign in Wilson disease. Eur J Pediatrics. 1989;148(6):548–9.

23. Lugassy G, Michaeli J, Oren R. Wilson's disease presenting as isolated arthritis of the hip. Arthritis rheumatism. 1988;31(4):573–5.

24. Rosen JM, Kuntz N, Melin-Aldana H, Bass LM. Spasmodic muscle cramps and weakness as presenting symptoms in Wilson disease. Pediatrics. 2013;132(4):e1039–42.
25. Kaushansky A, Frydman M, Kaufman H, Homburg R: **Endocrine studies of the ovulatory disturbances in Wilson’s disease (hepatolenticular degeneration).** *Fertility and sterility* 1987, 47(2):270–273.

26. Klee JG. Undiagnosed Wilson's disease as cause of unexplained miscarriage. *Lancet.* 1979;2(8139):423.

27. Tarnacka B, Rodo M, Cichy S, Członkowska A. Procreation ability in Wilson's disease. *Acta Neurol Scand.* 2000;101(6):395–8.

28. Krysiak R, Okopien B. [Whipple's triad as a clinical manifestation of hepatolenticular degeneration]. *Pol Arch Med Wewn.* 2007;117(3):53–5.

29. Factor SM, Cho S, Sternlieb I, Scheinberg IH, Goldfischer S. The cardiomyopathy of Wilson's disease. Myocardial alterations in nine cases. *Virchows Archiv A Pathological anatomy histology.* 1982;397(3):301–11.

30. Weizman Z, Picard E, Barki Y, Moses S. Wilson's disease associated with pancreatitis. *J Pediatr Gastroenterol Nutr.* 1988;7(6):931–3.

31. Nussinson E, Shahbari A, Shibli F, Chervinsky E, Trougouboff P, Markel A. Diagnostic challenges of Wilson's disease presenting as acute pancreatitis, cholangitis, and jaundice. *World journal of hepatology.* 2013;5(11):649–53.

32. Nandi M, Sarkar S, Mondal R. Generalized hyperpigmentation in Wilson's disease: An unusual association. *Journal of neurosciences in rural practice.* 2013;4(1):70–2.

33. Thaipisuttikul Y. Acanthosis nigricans associated with hepatolenticular degeneration. *J Dermatol.* 1997;24(6):395–400.

**Tables**

**Table 1**

| Exon score | Location | Nucleotide mutation | Amino acid alteration | Allele         | known pathogenic |
|------------|----------|---------------------|----------------------|----------------|-----------------|
| 8          | 2333     | G>T                 | p.Arg778Lcu          | heterozygote   | mutations       |
| 11         | 2621     | C>T                 | p.Ala874Val          | heterozygote   | suspicious pathogenic mutations |

**Table 2**

Possible clinical manifestations of WD
| Target organ                        | Clinical features                                                                                                                                 |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| liver                             | Abnormal liver enzymes, asymptomatic hepatomegaly, acute or chronic hepatitis, cirrhosis, hepatic encephalopathy, and fulminant hepatitis[4]       |
| nervous system                    | Motor dysfunctions: dystonias, prkinsonism, choreoathetosis, tremor, and ataxias, Dysarthria, Oropharyngeal disfunctions. Seizures[17]; Nonmotor symptoms: school failure, personality disorders, mood changes, psychosis, cognitive abnormalities, sleep disorders, and autonomic disturbances, impulsiveness, sexual exhibitionism, inappropriate behavior[17] |
| Ophthalmologic manifestations     | Kayser–Fleischer ring, sunflower cataract[18]; slowing of saccades, impaired upgaze, and strabismus                                                      |
| blood                             | Hemolytic anemia, coombs-negative hemolytic anemia, HELLP syndrome; leukopenia                                                                     |
| kidney                            | Glomerulonephritis; nephrotic syndrome; renal tubular function disorder; renal tubular acidosis, aminoaciduria; IgA nephropathy; IgM nephropathy; Fanconi syndrome; nephrolithiasis |
| Musculoskeletal and joint diseases| Osteoporosis; osseomuscular; arthritis or arthralgias; muscle weakness[24]                                                                       |
| Endocrine system                  | Male feminization; paramenia; habitual abortion; infertility, sexual retardation; hyperprolactinemia; hypoparathyroidism; insulinoma; hypokalemia  |
| Cardiovascular system             | Electrocardiographic abnormalities; cardiac interstitial fibrosis, myocarditis[29]                                                                |
| others                            | Pancreatitis; cholangitis; hyperpigmentation; acanthosis nigricans[33]                                                                            |
Figure 1

A Light microscopy of the kidney showed mesangial cells and matrix proliferation of glomeruli (H&E stain, ×400). B Light microscopy showed brushing margins disappeared and lumen dilated of partial renal tubules, renal interstitial edema and inflammatory cell infiltration (H&E ×400). C Immunofluorescence staining of the kidney showed bright granular depositon of IgA (×400). D Silver staining of the kidney showed tubule bristles shed and interstitial edema(×400).
Figure 2

A Light microscopy of the kidney showed granular deposition in the cytoplasm of renal tubules epithelial cells (H&E stain, ×400). B Some renal tubular epithelial cells showed degeneration of mitochondria in the cytoplasm. The size of mitochondria varied, the inner and outer membranes were separated, and the cristae became shorter and disappeared by electron microscopy (×7500). C Electron microscopy of some round granules deposition in the lysosome (×7500). D Brown to black deposits in renal tubular epithelial cells by TIMM’S copper staining (×400)

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- CAREChecklist.docx